Agios Presents Updated Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma
Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Ivosidenib in Greater China
Forte Minerals Appoints Patrick Evans as Non-Executive Chairman and Announces the Resignation of Long-Standing Director Doug Turnbull
